RVL Pharmaceuticals plc

RVLPQ

IE00BF2HDL56

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 07:18:55 22/05/2024 pm IST			5-day change	1st Jan Change
0.0001 ^USD	+9,900.00%		0.00%	-96.67%

12/04	North American Morning Briefing : Big Banks Kick -2-	DJ
21/03	North American Morning Briefing : Investors -2-	DJ

RVL Pharmaceuticals plc Reaffirms Sales Guidance for the Fourth Quarter of 2022

November 11, 2022 at 02:35 am IST

RVL Pharmaceuticals plc reaffirmed sales guidance for the fourth quarter of 2022. For the period, the company expects the net sales of UPNEEQ to be $12 to $14 million, representing sequential growth of 20% to 40% compared to the third quarter of 2022.

Latest news about RVL Pharmaceuticals plc

North American Morning Briefing : Big Banks Kick -2-	12/04	DJ
North American Morning Briefing : Investors -2-	21/03	DJ
North American Morning Briefing : TSMC Results -2-	18/01	DJ
North American Morning Briefing : Focus Fixed on Latest Inflation Print	11/01	DJ
North American Morning Briefing : S&P 500 Futures -2-	04/01	DJ
North American Morning Briefing : S&P 500 Futures Just Shy of Record High	28/12	DJ
North American Morning Briefing : Stock Futures -2-	21/12	DJ
North American Morning Briefing : Dow Set For New -2-	14/12	DJ
North American Morning Briefing : Stock Futures Struggle to Extend Rally Ahead of More Jobs Data	07/12	DJ
RVL Pharmaceuticals plc(NasdaqGS:RVLP) dropped from S&P TMI Index	25/23/25	CI
RVL Pharmaceuticals plc(NasdaqGS:RVLP) dropped from NASDAQ Composite Index	20/23/20	CI
Health Care Down as Risk Aversion Hurts Biotech -- Health Care Roundup	13/23/13	DJ
Sector Update: Health Care Stocks Decline in Late Afternoon	13/23/13	MT
Top Midday Decliners	12/23/12	MT
Sector Update: Health Care Stocks Lower Thursday Afternoon	12/23/12	MT
RVL Pharmaceuticals Subsidiaries File for Prepackaged Chapter 11 Change of Control to Lenders	12/23/12	MT
Wall Street Set to Open Higher; Personal Consumption Inflation Data Lower Than Expected	29/23/29	MT
Top Premarket Gainers	29/23/29	MT
RVL Pharmaceuticals plc Announces Resignation of Joaquin Benes and Juan Vergez from the Board of Directors	23/23/23	CI
HC Wainwright Adjusts RVL Pharmaceuticals Price Target to $3 From $4, Maintains Buy Rating	21/23/21	MT
Sector Update: Health Care Stocks Decreasing Late Afternoon	17/23/17	MT
Sector Update: Health Care	17/23/17	MT
Top Midday Decliners	16/23/16	MT
Transcript : RVL Pharmaceuticals plc, Q2 2023 Earnings Call, Aug 14, 2023	14/23/14
Earnings Flash (RVLP) RVL PHARMACEUTICALS Posts Q2 Revenue $8.3M, vs. Street Est of $10.3M	14/23/14	MT

Chart RVL Pharmaceuticals plc

Duration

Period

More charts

Company Profile

RVL Pharmaceuticals plc is a specialty pharmaceutical company. The Company is focused on the commercialization of UPNEEQ, or RVL-1201 (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults. It is focused on growing Upneeq with eye care and medical aesthetic professionals and providing a prescription experience for patients through its pharmacy. RVL Pharmacy dispenses Upneeq only. The Company is also developing Arbaclofen ER tablets for the alleviation of spasticity in multiple sclerosis patients. Its target patient population comprises adults with droopy or low-lying eyelids or acquired ptosis, the majority of whom are female. Its healthcare provider customers include optometrists, ophthalmologists, oculoplastic surgeons, facial plastic surgeons, dermatologists, and practitioners qualified to diagnose and treat acquired blepharoptosis in adults.

Sector

Pharmaceuticals

Calendar

12/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
RVL PHARMACEUTICALS PLC	-96.67%	11.14T
CSL LIMITED	-2.00%	9TCr
SAMSUNG BIOLOGICS CO.,LTD.	-1.18%	3.92TCr
BIOGEN INC.	-15.83%	3.17TCr
UCB	+62.86%	2.65TCr
BIOMARIN PHARMACEUTICAL INC.	-21.68%	1.43TCr
INCYTE CORPORATION	-8.73%	1.29TCr
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-15.05%	1.12TCr
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-45.69%	1.1TCr
SWEDISH ORPHAN BIOVITRUM AB	+4.94%	894.43Cr

Biopharmaceuticals